FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?

J Hepatol. 2014 Jul;61(1):164-5. doi: 10.1016/j.jhep.2014.03.024. Epub 2014 Mar 27.

Authors

Alexandre Liccioni¹, Maria Reig¹, Jordi Bruix²

Affiliations

¹ BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain.
² BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain. Electronic address: jbruix@clinic.ub.es.

PMID: 24681343
DOI: 10.1016/j.jhep.2014.03.024

No abstract available

Keywords: BCLC; HCC; Treatment.

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Female
Humans
Liver Neoplasms / drug therapy*
Male
Palliative Care*